BRKR

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Bruker Corporation to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Technology, Research, Medical Devices, Other Technology, Nanotechnology, Health Technology, Biotechnology, Health, Science, CFO, Corporation, Conference, Bruker, BRKR

Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:
    TD Cowen 44th Annual Health Care Conference in Boston, MA
    Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com .
  • Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.

Bruker Announces Quarterly Dividend

Retrieved on: 
Friday, February 16, 2024
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Electronic Design Automation, Technology, Corporation, Bruker, BRKR

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024.

Key Points: 

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024.

Bruker Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 13, 2024
Research, Technology, Medical Devices, Nanotechnology, Biotechnology, Hardware, Pharmaceutical, Health, Science, Other Science, Acquisition, PIN, Bruker, Telephone, Growth, BSI, Table, Conference, GAAP, Webcast, BRKR, BEST, FY, EPS, Corporation, Pharmaceutical industry

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2023.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2023.
  • Q4 2023 Bruker Scientific Instruments (BSI) revenues of $783.6 million increased 20.2% yoy, with organic revenue growth of 15.5%.
  • Q4 2023 Bruker Energy & Supercon Technologies (BEST) revenues of $75.2 million increased 27.7% yoy, with organic revenue growth, net of intercompany eliminations, of 20.3%.
  • [1] In Q4 2023, Bruker recorded a GAAP gain of $144.1 million, or $0.99 per share, in connection with the PhenomeX acquisition, which closed on October 2, 2023.

Bruker Acquires Nanophoton Corporation, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience

Retrieved on: 
Wednesday, February 7, 2024
Technology, Nanotechnology, Health, Manufacturing, Other Health, Other Science, Other Technology, Health Technology, Hardware, Science, Other Manufacturing, Electronic Design Automation, Semiconductor, Medical Supplies, Multimedia, Polymer, Growth, BRKR, Research, History, Excipient, Acquisition, Tissue, Corporation, Tablet, Microscope

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation , a pioneer focused on advanced research Raman microscopy systems.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation , a pioneer focused on advanced research Raman microscopy systems.
  • Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers, primarily in Japan.
  • This acquisition fills a gap in Bruker’s molecular microscopy portfolio, and Bruker is looking forward to offering fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.
  • We are look forward to this new opportunity to bring the differentiated Nanophoton Raman imaging systems to our research customers worldwide with global support.”
    Financial terms of the transaction were not disclosed.

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

Retrieved on: 
Tuesday, February 6, 2024
Research, Hardware, Pharmaceutical, Optical, Data Management, Technology, Medical Devices, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Multimedia, BRKR, History, Bruker, Animal, AMI, FLI, Fluorescence, SII, Acquisition, BLI, Corporation, PCI, Medical imaging

Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC , a leader in preclinical in-vivo optical imaging systems.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC , a leader in preclinical in-vivo optical imaging systems.
  • This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening its range of preclinical solutions for disease research.
  • “Spectral Instruments Imaging systems perfectly complement the Bruker Preclinical offering,” said Keith Copeland, the CEO of SII.
  • Their advanced BLI, FLI and X-ray imaging systems complement our portfolio to better serve the diverse needs of our preclinical customers.

Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast

Retrieved on: 
Tuesday, February 6, 2024
Technology, Research, Nanotechnology, Health Technology, Biotechnology, Health, Electronic Design Automation, Pharmaceutical, Science, Telephone, Corporation, Bruker, BRKR, PIN, Webcast, Conference, Broadcasting

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024.
  • To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q4 2023 Earnings Webcast” hyperlink in the “Events & Presentations” section.
  • A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins.
  • Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s Fourth Quarter 2023 Earnings Conference Call”.

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Retrieved on: 
Monday, February 5, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, General Health, Data Analytics, Health Technology, Science, Data Management, Multimedia, Microfluidics, Kinetics, Fraunhofer Society, BRKR, SPR, Cell therapy, Surface plasmon resonance, Thermodynamics, Bruker, Drug, Drug discovery, Exhibition, Immunology, API, Acquisition, Automation, Software, Conference

At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.

Key Points: 
  • At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
  • The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality.
  • View the full release here: https://www.businesswire.com/news/home/20240205314598/en/
    ‘Triceratops’ SPR #64: the all new, high-throughput multiplexing Surface Plasmon Resonance (SPR) system (Photo: Business Wire)
    The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots.
  • With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.

Bruker Announces Agreement to Acquire Chemspeed

Retrieved on: 
Thursday, January 25, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, FLEX, Food, Data management, Multimedia, Corporation, QC, Workflow, Cosmetics, Acquisition, Laboratory, Robotics, Automation, BRKR, Fine chemical

Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG , a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG , a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.
  • Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications.
  • Chemspeed automation is used every day in top R&D and QC laboratories globally, setting standards in lab automation.
  • Their commitment to excellence is reflected in the wide range of Chemspeed automation, and their dedication to customer service.”

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

Retrieved on: 
Thursday, January 4, 2024
Electronic Design Automation, Health, Technology, Health Technology, Nanotechnology, Pharmaceutical, Biotechnology, Process, Multimedia, Acquisition, BRKR, PAT, Immersion

Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc. , a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications.

Key Points: 
  • Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc. , a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications.
  • Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker’s biopharma PAT portfolio with its well-established products.
  • Dr. Andreas Kamlowski, President of Bruker Optics, stated: “The acquisition of Tornado process Raman technology and product is a great fit to expand our range of biopharma PAT analyzers.
  • We warmly welcome the talented Tornado team with valuable applications expertise and years of experience.”
    Mr. Ambrish Jaiswal, the CEO of Tornado Spectral Systems, commented: “The Tornado team is proud to join Bruker.